文献速递神经肿瘤

成人弥漫性中线胶质瘤H3 K27变异型手术切除的临床、手术与分子特征及结局

Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection.
PubMed 文献 · J Neurooncol · 2026-07-02

该回顾性研究分析了52例接受手术切除的成人大脑H3 K27变异型弥漫性中线胶质瘤患者,中位总生存期为17.8个月。基因组分析显示H3F3A突变主导且TP53高频共存,RTK/RAS/PI3K通路突变显著富集。多因素分析中术后辅助放疗(RT+TMZ)是唯一独立保护因素(HR=0.12,P<0.001)。

要点

  • 成人H3 K27变异型DMG中位OS为17.8个月。
  • 术后辅助放疗(RT+TMZ)是唯一独立保护因素(HR=0.12,P<0.001)。
  • 切除程度与分子靶向治疗未达独立统计学意义。

核心结论

  • 成人H3 K27变异型DMG是生物学独特实体,具有独特基因组改变。
  • 术后放疗(RT+TMZ)仍是不可替代的预后基石,最大安全切除提供必要的减瘤基础。

研究设计与样本

  • 回顾性分析52例接受手术切除的成人大脑H3 K27变异型DMG患者。
  • 对其中20例进行下一代测序(NGS)以表征基因组景观。
  • 采用Kaplan-Meier分析和Cox比例风险模型评估生存结局。

主要发现

  • 中位总生存期(OS)为17.8个月。
  • 基因组分析显示H3F3A突变主导,TP53突变高频共存。
  • RTK/RAS/PI3K信号通路突变显著富集,主要由NF1、FGFR1和PIK3CA驱动。
  • 多因素Cox回归中,术后辅助放疗(RT+TMZ)是OS唯一独立保护因素(HR=0.12,P<0.001)。
  • 切除程度(RANO EOR分级)和分子靶向治疗虽在单因素分析中显示有利生存趋势,但未达独立统计学意义。

临床怎么用

  • 术后应优先考虑辅助放疗(RT+TMZ)以改善生存。
  • 最大安全切除可作为细胞减灭基础,但需结合放疗等综合治疗。
  • 未来治疗范式应将安全切除与靶向药物整合入成人量身定制的多模式框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the clinical, surgical, and molecular features and outcomes of adult patients with diffuse midline glioma (DMG), H3 K27-altered, treated with surgical resection. METHODS: We retrospectively analyzed 52 adult patients with cerebral H3 K27-altered DMG who underwent surgical resection. Next-generation sequencing (NGS) was performed on a subset (n = 20) to characterize the genomic landscape. Survival outcomes were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: The median overall survival (OS) was 17.8 months. Genomic profiling revealed a distinct molecular landscape dominated by H3F3A mutations, with high-frequency co-occurring TP53 mutation. Crucially, we observed a significant enrichment of mutations within the RTK/RAS/PI3K signaling pathway, primarily driven by NF1, FGFR1, and PIK3CA. In the multivariable Cox regression model, postoperative adjuvant radiotherapy (RT + TMZ) emerged as the sole independent protective factor for overall survival (HR = 0.12, P < 0.001). Conversely, the extent of resection (RANO EOR Class) and molecular targeted therapy did not reach independent statistical significance, despite demonstrating favorable survival trends in univariable analyses. CONCLUSION: Adult H3 K27-altered DMG represents a biologically unique entity with distinct genomic alterations. While postoperative radiotherapy (RT + TMZ) remains the irreplaceable prognostic cornerstone, maximal safe resection provides an essential cytoreductive foundation. Future paradigms should integrate safe resection and targeted agents into adult-tailored, multi-modal treatment frameworks.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lin J, Tang W, Li K, et al. Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection. J Neurooncol. 2026. PMID: 42390632. doi:10.1007/s11060-026-05690-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。